Search / 382 results found

from
to
  • Updated

BRONX, N.Y., Oct. 21, 2021 /PRNewswire/ -- Armed with a novel strategy they developed for bolstering the body's immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional cure for HIV and other chronic viral infections. Their findings were published today in the Journal of Clinical Investigation.

  • Updated

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Today Nutrafol, the pioneer of the hair wellness category, announced the launch of its newest innovation: Growth Activator, a hair serum made with plant-derived exosomes from Ashwagandha seeds. The new, revolutionary hair serum is the first scalp-care product that leverages the science of plant exosome technology to boost cellular renewal on the scalp for thicker-looking hair.

  • Updated

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the appointment of Valerie M. Jansen, M.D., Ph.D., as Chief Medical Officer. Dr. Jansen was promoted from her prior role as Vice President, Clinical Development.

  • Updated

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Project ALS, a non-profit 501(c)3 leader in the pursuit of treatments and a cure for the neurodegenerative disease ALS, has announced its research advisory board (RAB).

  • Updated

NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn's disease tissues will be used to investigate the therapeutic potential of Hoth's HT-003 drugs. All testing will be performed at REPROCELL's Centre for Predictive Drug Discovery in Glasgow.

  • Updated

TORONTO, Oct. 19, 2021 /PRNewswire/ -- The results of a pivotal clinical trial on hair loss in women have been published in The Lancet's journal, EClinicalMedicine, and the paper has been placed in The Lancet's Specialty Collection on Regenerative Medicine.[1] The investigation studied the patent-pending botanical Replenology® hair system from Arbor Life Labs, which is designed to promote healthy hair growth, prevent hair loss and activate dormant hair follicles.*[2]

  • Updated

RYE BROOK, N.Y., Oct. 18, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering amazing deals to customers every time they shop, are teaming up for the 20th consecutive year to raise critical funds for lifesaving research and treatments for children with blood cancer. In honor of this milestone, Burlington has made a commitment to raise funds with the help of their customers in support of the LLS Children's Initiative, dedicated to supporting children and their families impacted by the disease. Funds raised in Burlington store locations nationwide will support the research pillar of the LLS Children's Initiative, enabling the organization to add more pediatric research grants to break down the barriers that stand in the way of pediatric cancer care innovation, as well as further the mission of LLS.

  • Updated

TEL AVIV, Israel, Oct. 18, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCF), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company"), today announced the publication of a manuscript that teaches the uses of its proprietary drug candidate SCI-110 for Tourette Syndrome (TS). The study was conducted at the Department of Psychiatry, and the Child Study Center at Yale University in New Haven, Connecticut, USA.